118 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
of linvoseltamab, a bispecific antibody targeting BCMA and CD3, in patients with relapsed/refractory multiple myeloma at the 65th American Society … 31, 2024, and a regulatory application is also under review in the EU.
The Company presented, at European Society for Medical Oncology Immuno-Oncology
8-K
EX-99.1
sr2vxe ssx
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
SC TO-T
EX-99
6963wx
25 Aug 23
Third party tender offer statement
7:46am
8-K
EX-99.1
oz9dzku0
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
PX14A6G
sv36uyw979 hz
18 May 23
Letter to shareholders
4:46pm
8-K
EX-99.1
usddk
3 Nov 22
Regeneron Reports Third Quarter 2022 Financial and Operating Results
7:19am
SC TO-T
EX-99
g5yxys
2 May 22
Third party tender offer statement
7:48am
DEFA14A
f4xq281 5u6atose
21 Apr 22
Additional proxy soliciting materials
4:21pm
8-K
EX-10.1
oxfx8rbwwg
8 Mar 22
Entry into a Material Definitive Agreement
6:15am
8-K
EX-99.1
s3iiu7 hdl5xtj6m8i6
4 Feb 22
Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
7:29am